Radiopharm Theranostics Ltd (AU:RAD) — Stock Price
Radiopharm Theranostics Ltd (AU:RAD) is currently trading at AU$0.01 AUD, up 8.33% today. Over the past 52 weeks, shares have ranged between AU$0.01 and AU$0.04. This page tracks Radiopharm Theranostics Ltd's live share price on the AU exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see RAD market cap overview.
Radiopharm Theranostics Ltd (RAD) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Radiopharm Theranostics Ltd's daily closing share price and trading volume on the AU exchange over the past year, giving a clear view of recent price momentum and liquidity.
Radiopharm Theranostics Ltd Income Statement — Revenue, Profit & Earnings by Year
Radiopharm Theranostics Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | AU$13.40 Million | AU$299.23K | AU$292.36K | AU$8.83K | AU$0.00 |
| Cost of Revenue | AU$3.59 Million | AU$21.61 Million | AU$3.30 Million | AU$2.98 Million | — |
| Gross Profit | AU$9.81 Million | AU$-21.31 Million | AU$-3.00 Million | AU$-2.97 Million | — |
| Research & Development | AU$27.52 Million | AU$17.56 Million | AU$22.03 Million | AU$7.49 Million | — |
| SG&A | AU$14.64 Million | AU$13.04 Million | AU$13.02 Million | AU$12.44 Million | AU$300.64K |
| Total Operating Expenses | AU$47.98 Million | AU$27.56 Million | AU$37.29 Million | AU$16.94 Million | AU$484.75K |
| Operating Income | AU$-38.17 Million | AU$-47.21 Million | AU$-40.29 Million | AU$-19.92 Million | AU$-484.75K |
| EBITDA | AU$-31.65 Million | AU$-45.38 Million | AU$-37.11 Million | AU$-18.04 Million | AU$-484.75K |
| EBIT | AU$-34.24 Million | AU$-48.50 Million | AU$-40.40 Million | AU$-21.03 Million | AU$-1.65 Million |
| Interest Expense | AU$65.30K | AU$642.89K | AU$86.09K | AU$9.35 Million | AU$0.00 |
| Income Before Tax | AU$-38.24 Million | AU$-47.85 Million | AU$-40.49 Million | AU$-30.29 Million | AU$-485.19K |
| Income Tax Expense | AU$103.29K | AU$96.36K | AU$38.01K | AU$44.40K | AU$-1.16 Million |
| Net Income | AU$-36.70 Million | AU$-47.95 Million | AU$-34.61 Million | AU$-30.34 Million | AU$-485.19K |
Radiopharm Theranostics Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Radiopharm Theranostics Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | AU$86.48 Million | AU$72.04 Million | AU$74.95 Million | AU$83.38 Million | AU$33.44K |
| Total Current Assets | AU$39.85 Million | AU$22.85 Million | AU$16.30 Million | AU$27.26 Million | AU$33.44K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | AU$10.40 Million | AU$987.41K | AU$4.47 Million | AU$56.48K | AU$6.35K |
| Inventory | — | AU$-987.41K | — | AU$1.00 | AU$-6.35K |
| Property, Plant & Equipment | AU$53.47K | AU$60.80K | AU$68.33K | AU$1.58K | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | AU$43.61 Million | AU$44.68 Million | AU$29.37 Million | AU$20.42 Million | AU$158.14K |
| Total Current Liabilities | AU$14.93 Million | AU$17.58 Million | AU$13.23 Million | AU$7.88 Million | AU$158.14K |
| Long-term Debt | — | — | — | — | — |
| Net Debt | AU$-29.12 Million | AU$-18.58 Million | AU$-11.70 Million | AU$-26.98 Million | AU$31.91K |
| Total Stockholder Equity | AU$44.79 Million | AU$28.12 Million | AU$44.38 Million | AU$62.96 Million | AU$-124.70K |
| Retained Earnings | AU$-145.73 Million | AU$-111.34 Million | AU$-65.35 Million | AU$-30.82 Million | AU$-485.19K |
Radiopharm Theranostics Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Radiopharm Theranostics Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | AU$-36.65 Million | AU$-22.98 Million | AU$-23.20 Million | AU$-9.91 Million | AU$-32.91K |
| Capital Expenditures | AU$0.00 | AU$5.00 | AU$1.53 Million | AU$28.34 Million | AU$2.75K |
| Free Cash Flow | AU$-36.65 Million | AU$-22.98 Million | AU$-24.73 Million | AU$-38.25 Million | AU$-32.91K |
| Investing Cash Flow | AU$1.77 Million | AU$0.00 | AU$-1.53 Million | AU$-28.37 Million | AU$-28.38 Million |
| Financing Cash Flow | AU$45.43 Million | AU$29.88 Million | AU$9.22 Million | AU$65.11 Million | AU$60.00K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | AU$1.90 Million | AU$2.64 Million | AU$3.04 Million | AU$4.80 Million | AU$862.77K |
| Depreciation | AU$2.60 Million | AU$3.13 Million | AU$3.30 Million | AU$2.98 Million | AU$2.98 Million |
| Change in Cash | AU$10.54 Million | AU$6.88 Million | AU$-15.28 Million | AU$26.95 Million | AU$27.09K |
Radiopharm Theranostics Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Radiopharm Theranostics Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 03, 2026 | 0.00 | 0.00 | +100.00% |
| Feb 26, 2026 | 0.00 | 0.00 | +100.00% |
| Dec 03, 2025 | -0.01 | 0.00 | -9900.00% |
| Sep 16, 2025 | -0.01 | 0.00 | -9900.00% |
| May 28, 2025 | -0.01 | 0.00 | -9900.00% |
| Feb 28, 2025 | -0.01 | -0.01 | +0.00% |
| Nov 27, 2024 | -0.01 | 0.00 | -9900.00% |
| Aug 29, 2024 | -0.04 | 0.00 | -9900.00% |